<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39327555</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1478-811X</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>26</Day></PubDate></JournalIssue><Title>Cell communication and signaling : CCS</Title><ISOAbbreviation>Cell Commun Signal</ISOAbbreviation></Journal><ArticleTitle>Oncogenic potential of SARS-CoV-2-targeting hallmarks of cancer pathways.</ArticleTitle><Pagination><StartPage>447</StartPage><MedlinePgn>447</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">447</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12964-024-01818-0</ELocationID><Abstract><AbstractText>The 2019 outbreak of SARS-CoV-2 has caused a major worldwide health crisis with high rates of morbidity and death. Interestingly, it has also been linked to cancer, which begs the issue of whether it plays a role in carcinogenesis. Recent studies have revealed various mechanisms by which SARS-CoV-2 can influence oncogenic pathways, potentially promoting cancer development. The virus encodes several proteins that alter key signaling pathways associated with cancer hallmarks. Unlike classical oncogenic viruses, which transform cells through viral oncogenes or by activating host oncogenes, SARS-CoV-2 appears to promote tumorigenesis by inhibiting tumor suppressor genes and pathways while activating survival, proliferation, and inflammation-associated signaling cascades. Bioinformatic analyses and experimental studies have identified numerous interactions between SARS-CoV-2 proteins and cellular components involved in cancer-related processes. This review explores the intricate relationship between SARS-CoV-2 infection and cancer, focusing on the regulation of key hallmarks driving initiation, promotion and progression of cancer by viral proteins. By elucidating the underlying mechanisms driving cellular transformation, the potential of SARS-CoV-2 as an oncovirus is highlighted. Comprehending these interplays is essential to enhance our understanding of COVID-19 and cancer biology and further formulating strategies to alleviate SARS-CoV-2 influence on cancer consequences.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jaiswal</LastName><ForeName>Aishwarya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cancer Biology Laboratory, School of Life Sciences, Jawaharlal Nehru University, New Delhi, 110067, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shrivastav</LastName><ForeName>Sanah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>SRM Institute of Science and Technology, Delhi-NCR Campus, Ghaziabad, Uttar Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kushwaha</LastName><ForeName>Hemant R</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>School of Biotechnology, Jawaharlal Nehru University, New Delhi, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Special Centre for Systems Medicine, Jawaharlal Nehru University, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaturvedi</LastName><ForeName>Rupesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Biotechnology, Jawaharlal Nehru University, New Delhi, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Special Centre for Systems Medicine, Jawaharlal Nehru University, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Rana P</ForeName><Initials>RP</Initials><Identifier Source="ORCID">0000-0003-4261-7044</Identifier><AffiliationInfo><Affiliation>Cancer Biology Laboratory, School of Life Sciences, Jawaharlal Nehru University, New Delhi, 110067, India. rana_singh@mail.jnu.ac.in.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Special Centre for Systems Medicine, Jawaharlal Nehru University, New Delhi, India. rana_singh@mail.jnu.ac.in.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA. rana_singh@mail.jnu.ac.in.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Cancer-Covid-19</GrantID><Agency>Indian Council of Medical Research</Agency><Country /></Grant><Grant><GrantID>Cancer-Covid-19</GrantID><Agency>Indian Council of Medical Research</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cell Commun Signal</MedlineTA><NlmUniqueID>101170464</NlmUniqueID><ISSNLinking>1478-811X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063646" MajorTopicYN="N">Carcinogenesis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cancer hallmarks</Keyword><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">Oncovirus</Keyword><Keyword MajorTopicYN="N">Tumorigenesis</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>7</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>23</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39327555</ArticleId><ArticleId IdType="pmc">PMC11426004</ArticleId><ArticleId IdType="doi">10.1186/s12964-024-01818-0</ArticleId><ArticleId IdType="pii">10.1186/s12964-024-01818-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data, https://covid19.who.int/. Accessed 14 Sep 2023.</Citation></Reference><Reference><Citation>Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2: structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol. 2020;25(10):587269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7723891</ArticleId><ArticleId IdType="pubmed">33324574</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, Hosein Z, Padda I, Mangat J, Altaf M. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med. 2020;2:1069–76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314621</ArticleId><ArticleId IdType="pubmed">32838147</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatmawati F, Mulyanti S. Risk factors associated with the severity of COVID-19. Malays J Med Sci. 2023;30(3):84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10325129</ArticleId><ArticleId IdType="pubmed">37425387</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo A, Pisaturo M, Zollo V, Martini S, Maggi P, Numis FG, Gentile I, Sangiovanni N, Rossomando AM, Bianco V, Calabria G. Obesity as a Risk Factor of Severe Outcome of COVID-19: A Pair-Matched 1: 2 Case-Control Study. J Clin Med. 2023;12(12):4055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10298877</ArticleId><ArticleId IdType="pubmed">37373748</ArticleId></ArticleIdList></Reference><Reference><Citation>Jyotsana N, King MR. The impact of COVID-19 on cancer risk and treatment. Cell Mol Bioeng. 2020;13(4):285–91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323371</ArticleId><ArticleId IdType="pubmed">32837583</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, Zhang Z, You H, Wu M, Zheng Q, Xiong Y. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783–91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7309152</ArticleId><ArticleId IdType="pubmed">32345594</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee LY, Cazier JB, Angelis V, Arnold R, Bisht V, Campton NA, Chackathayil J, Cheng VW, Curley HM, Fittall MW, Freeman-Mills L. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395(10241):1919–26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255715</ArticleId><ArticleId IdType="pubmed">32473682</ArticleId></ArticleIdList></Reference><Reference><Citation>Durham AL, Adcock IM. The relationship between COPD and lung cancer. Lung Cancer. 2015;90(2):121–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4718929</ArticleId><ArticleId IdType="pubmed">26363803</ArticleId></ArticleIdList></Reference><Reference><Citation>Parris BA, O’Farrell HE, Fong KM, Yang IA. Chronic obstructive pulmonary disease (COPD) and lung cancer: common pathways for pathogenesis. J Thorac Dis. 2019;11(Suppl 17):S2155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6831920</ArticleId><ArticleId IdType="pubmed">31737343</ArticleId></ArticleIdList></Reference><Reference><Citation>Avogaro A. Diabetes and obesity: the role of stress in the development of cancer. Endocrine. 2024;3:1.</Citation><ArticleIdList><ArticleId IdType="pubmed">38831236</ArticleId></ArticleIdList></Reference><Reference><Citation>Harborg S, Kjærgaard KA, Thomsen RW, Borgquist S, Cronin-Fenton D, Hjorth CF. New horizons: epidemiology of obesity, diabetes mellitus, and cancer prognosis. J Clin Endocrinol Metab. 2024;109(4):924–35.</Citation><ArticleIdList><ArticleId IdType="pubmed">37552777</ArticleId></ArticleIdList></Reference><Reference><Citation>Connaughton M, Dabagh M. Association of hypertension and organ-specific cancer: a meta-analysis. Healthcare. 2022;10(6):1074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9222904</ArticleId><ArticleId IdType="pubmed">35742125</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettorre GM, Patel M, Gennari A, Pentheroudakis G, Romano E, Cortellini A, Pinato DJ. The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer. ESMO Open. 2021;6(3):100123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8026271</ArticleId><ArticleId IdType="pubmed">33932622</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, Kundu CN. Cancer and COVID-19: Why are cancer patients more susceptible to COVID-19? Med Oncol. 2021;38(9):101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8302962</ArticleId><ArticleId IdType="pubmed">34302557</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Guo M, Tian X, Wang X, Yang X, Wu P, Liu C, Xiao Z, Qu Y, Yin Y, Wang C. Virus-host interactome and proteomic survey reveal potential virulence factors influencing SARS-CoV-2 pathogenesis. Med. 2021;2(1):99–112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7373048</ArticleId><ArticleId IdType="pubmed">32838362</ArticleId></ArticleIdList></Reference><Reference><Citation>Souchelnytskyi S, Nera A, Souchelnytskyi N. COVID-19 engages clinical markers for the management of cancer and cancer-relevant regulators of cell proliferation, death, migration, and immune response. Sci Rep. 2021;11(1):5228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7933131</ArticleId><ArticleId IdType="pubmed">33664395</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O’Meara MJ, Rezelj VV, Guo JZ, Swaney DL, Tummino TA. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583(7816):459–68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7431030</ArticleId><ArticleId IdType="pubmed">32353859</ArticleId></ArticleIdList></Reference><Reference><Citation>Tutuncuoglu B, Cakir M, Batra J, Bouhaddou M, Eckhardt M, Gordon DE, Krogan NJ. The landscape of human cancer proteins targeted by SARS-CoV-2. Cancer Discov. 2020;10(7):916–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7357668</ArticleId><ArticleId IdType="pubmed">32444466</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan I, Hatiboglu MA. Can COVID-19 induce glioma tumorogenesis through binding cell receptors? Med Hypotheses. 2020;1(144):110009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7303027</ArticleId><ArticleId IdType="pubmed">32758869</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebrahimi Sadrabadi A, Bereimipour A, Jalili A, Gholipurmalekabadi M, Farhadihosseinabadi B, Seifalian AM. The risk of pancreatic adenocarcinoma following SARS-CoV family infection. Sci Rep. 2021;11(1):12948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8217230</ArticleId><ArticleId IdType="pubmed">34155232</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouhaddou M, Memon D, Meyer B, et al. The global phosphorylation landscape of SARS-CoV-2 infection. Cell. 2020;182:685–712.e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7321036</ArticleId><ArticleId IdType="pubmed">32645325</ArticleId></ArticleIdList></Reference><Reference><Citation>Langerbeins P, Hallek M. COVID-19 in patients with hematologic malignancy. Blood. 2022;140(3):236–52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9098396</ArticleId><ArticleId IdType="pubmed">35544585</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonuomo V, Ferrarini I, Dell’Eva M, Sbisà E, Krampera M, Visco C. COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review. World J Virol. 2021;10(6):312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8641038</ArticleId><ArticleId IdType="pubmed">34909405</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta A, Vasudevan S, Parkash A, Sharma A, Vashist T, Krishna V. COVID-19 mortality in cancer patients: a report from a tertiary cancer centre in India. PeerJ. 2021;21(9):e10599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7827973</ArticleId><ArticleId IdType="pubmed">33552716</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinato DJ, Zambelli A, Aguilar-Company J, Bower M, Sng CC, Salazar R, Bertuzzi A, Brunet J, Mesia R, Segui E, Biello F. Clinical portrait of the SARS-CoV-2 epidemic in European patients with cancer. Cancer Discov. 2020;10(10):1465–74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7668225</ArticleId><ArticleId IdType="pubmed">32737082</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo H, Yan J, Gong R, Zhang D, Zhou X, Wang X. Identification of biomarkers and pathways for the SARS-CoV-2 infections in obstructive sleep apnea patients based on machine learning and proteomic analysis. BMC Pulm Med. 2024;24(1):112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10913609</ArticleId><ArticleId IdType="pubmed">38443855</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie E, Shen X, Yeo YH, Xing Z, Ebinger JE, Duan Y, Zhang Y, Cheng S, Ji F, Deng J. Exploring the underlying molecular mechanisms of acute myocardial infarction after SARS-CoV-2 infection. Am Heart J Plus. 2024;44:100417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11263507</ArticleId><ArticleId IdType="pubmed">39045234</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna G. Understanding the SARS-CoV-2–human liver interactome using a comprehensive analysis of the individual virus–host interactions. Livers. 2024;4(2):209–39.</Citation></Reference><Reference><Citation>Zhou X, Huang T, Pan H, Du A, Wu T, Lan J, Song Y, Lv Y, He F, Yuan K. Bioinformatics and system biology approaches to determine the connection of SARS-CoV-2 infection and intrahepatic cholangiocarcinoma. Plos One. 2024;19(4):e0300441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11034673</ArticleId><ArticleId IdType="pubmed">38648205</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang C, Sun H, Wen J, Wu X, Wu Q, Zhai D. Investigation of the relationship between COVID-19 and pancreatic cancer using bioinformatics and systems biology approaches. Medicine. 2024;103(31):e39057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11296473</ArticleId><ArticleId IdType="pubmed">39093763</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrarini MG, Lal A, Rebollo R, et al. Genome-wide bioinformatic analyses predict key host and viral factors in SARS-CoV-2 pathogenesis. Commun Biol. 2021;4(1):1–15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8128904</ArticleId><ArticleId IdType="pubmed">34002013</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Li L, Li M, Wang X. The SARS-CoV-2 host cell receptor ACE2 correlates positively with immunotherapy response and is a potential protective factor for cancer progression. Comput Struct Biotechnol J. 2020;18:2438–44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7462778</ArticleId><ArticleId IdType="pubmed">32905022</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong J, Yuan H, Yang J, Du Y, Li Z, Liu X, Yang H, Wang Z, Wang Z, Jiang L, Ren Z. Bioinformatics and system biology approach to identify potential common pathogenesis for COVID-19 infection and sarcopenia. Front Med. 2024;11:1378846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11228343</ArticleId><ArticleId IdType="pubmed">38978778</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhardwaj K, Liu P, Leibowitz JL, Kao CC. The coronavirus endoribonuclease Nsp15 interacts with retinoblastoma tumor suppressor protein. J Virol. 2012;86(8):4294–304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3318636</ArticleId><ArticleId IdType="pubmed">22301153</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma-Lauer Y, Carbajo-Lozoya J, Hein MY, Müller MA, Deng W, Lei J, Meyer B, Kusov Y, von Brunn B, Bairad DR, Hünten S. p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1. Proc Natl Acad Sci. 2016;113(35):E5192–201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024628</ArticleId><ArticleId IdType="pubmed">27519799</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu LH, Huang M, Fang SG, Liu DX. Coronavirus infection induces DNA replication stress partly through interaction of its nonstructural protein 13 with the p125 subunit of DNA polymerase δ. J Biol Chem. 2011;286(45):39546–59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234778</ArticleId><ArticleId IdType="pubmed">21918226</ArticleId></ArticleIdList></Reference><Reference><Citation>Fakhrolmobasheri M, Shiravi A, Zeinalian M. SARS-CoV-2 interaction with human dna methyl transferase 1: a potential risk for increasing the incidence of later chronic diseases in the survived patients. Int J Prev Med. 2022;13(1):23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8980824</ArticleId><ArticleId IdType="pubmed">35392323</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter M, Chen IP, Vallejo-Gracia A, Kim IJ, Bielska O, Lam VL, Hayashi JM, Cruz A, Shah S, Soveg FW, Gross JD. SIRT5 is a proviral factor that interacts with SARS-CoV-2 Nsp14 protein. PLoS Pathog. 2022;18(9):e1010811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9499238</ArticleId><ArticleId IdType="pubmed">36095012</ArticleId></ArticleIdList></Reference><Reference><Citation>Appelberg S, Gupta S, Svensson Akusjärvi S, Ambikan AT, Mikaeloff F, Saccon E, Végvári Á, Benfeitas R, Sperk M, Ståhlberg M, Krishnan S. Dysregulation in Akt/mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells. Emerg Microbes Infect. 2020;9(1):1748–60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7473213</ArticleId><ArticleId IdType="pubmed">32691695</ArticleId></ArticleIdList></Reference><Reference><Citation>Zalpoor H, Akbari A, Nabi-Afjadi M. Ephrin (Eph) receptor and downstream signaling pathways: a promising potential targeted therapy for COVID-19 and associated cancers and diseases. Hum Cell. 2022;35(3):952–4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8977187</ArticleId><ArticleId IdType="pubmed">35377105</ArticleId></ArticleIdList></Reference><Reference><Citation>Engler M, Albers D, Von Maltitz P, Groß R, Münch J, Cirstea IC. ACE2-EGFR-MAPK signaling contributes to SARS-CoV-2 infection. Life Sci Alliance. 2023;6(9).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10320016</ArticleId><ArticleId IdType="pubmed">37402592</ArticleId></ArticleIdList></Reference><Reference><Citation>Koya AI, Ibrahim SA. Carcinogenesis. StatPearls, https://www.ncbi.nlm.nih.gov/books/NBK604463/. Accessed 15 Aug 2024.</Citation><ArticleIdList><ArticleId IdType="pubmed">38917272</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi JD, Lee JS. Interplay between epigenetics and genetics in cancer. Genomics Inform. 2013;11(4):164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3897842</ArticleId><ArticleId IdType="pubmed">24465226</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarrado-Castellarnau M, de Atauri P, Cascante M. Oncogenic regulation of tumor metabolic reprogramming. Oncotarget. 2016;7(38):62726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5308762</ArticleId><ArticleId IdType="pubmed">28040803</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontomanolis EN, Koutras A, Syllaios A, Schizas D, Mastoraki A, Garmpis N, Diakosavvas M, Angelou K, Tsatsaris G, Pagkalos A, Ntounis T. Role of oncogenes and tumor-suppressor genes in carcinogenesis: a review. Anticancer Res. 2020;40(11):6009–15.</Citation><ArticleIdList><ArticleId IdType="pubmed">33109539</ArticleId></ArticleIdList></Reference><Reference><Citation>Sever R, Brugge JS. Signal transduction in cancer. Cold Spring Harb Perspect Med. 2015;5(4):a006098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4382731</ArticleId><ArticleId IdType="pubmed">25833940</ArticleId></ArticleIdList></Reference><Reference><Citation>Engel BE, Cress WD, Santiago-Cardona PG. The retinoblastoma protein: a master tumor suppressor acts as a link between cell cycle and cell adhesion. Cell Health Cytoskelet. 2014;18:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5228373</ArticleId><ArticleId IdType="pubmed">28090172</ArticleId></ArticleIdList></Reference><Reference><Citation>Albahde MA, Zhang P, Zhang Q, Li G, Wang W. Upregulated expression of TUBA1C predicts poor prognosis and promotes oncogenesis in pancreatic ductal adenocarcinoma via regulating the cell cycle. Front Oncol. 2020;14(10):49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7033491</ArticleId><ArticleId IdType="pubmed">32117719</ArticleId></ArticleIdList></Reference><Reference><Citation>Gui S, Chen P, Liu Y, Chen Q, Cheng T, Lv S, Zhou T, Song Z, Xiao J, He W, Yuan S. TUBA1C expression promotes proliferation by regulating the cell cycle and indicates poor prognosis in glioma. Biochem Biophys Res Commun. 2021;5(577):130–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">34517210</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao T, Gao Y, Liu X, Nie Z, Sun H, Lin K, Peng H, Wang S. Identification and functional analysis of the SARS-COV-2 nucleocapsid protein. BMC Microbiol. 2021;21:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7898026</ArticleId><ArticleId IdType="pubmed">33618668</ArticleId></ArticleIdList></Reference><Reference><Citation>Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009;9(12):874–85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951677</ArticleId><ArticleId IdType="pubmed">19935676</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakshmanan I, Rachagani S, Hauke R, Krishn SR, Paknikar S, Seshacharyulu P, Karmakar S, Nimmakayala RK, Kaushik G, Johansson SL, Carey GB. MUC5AC interactions with integrin β4 enhances the migration of lung cancer cells through FAK signaling. Oncogene. 2016;35(31):4112–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5745007</ArticleId><ArticleId IdType="pubmed">26751774</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariampillai AI, Dela Cruz JP, Suh J, Sivapiragasam A, Nevins K, Hindenburg AA. Evaluation of tumor marker cancer antigen 72–4 (CA 72–4) in the monitoring of metastatic or recurrent tumors of the gastrointestinal tract, lung, breast, and ovaries. 10.1200/JCO.2017.35.4_suppl.263</Citation><ArticleIdList><ArticleId IdType="pubmed">28668856</ArticleId></ArticleIdList></Reference><Reference><Citation>Pochampalli MR, Bitler BG, Schroeder JA. Transforming growth factor α–dependent cancer progression is modulated by Muc1. Cancer Res. 2007;67(14):6591–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17638868</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu W, Liu X, Wang T, Liu F, Zhu A, Lin Y, Luo J, Ye F, He J, Zhao J, Li Y. Elevated MUC1 and MUC5AC mucin protein levels in airway mucus of critical ill COVID-19 patients. J Med Virol. 2021;93(2):582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7436726</ArticleId><ArticleId IdType="pubmed">32776556</ArticleId></ArticleIdList></Reference><Reference><Citation>Knack R, Hanada TZ, Knack RS, Dana S, Afonso GL, Omena T, Mayr K, Knack RS. SARS-CoV-2, a possible new oncovirus. Qeios. 2023. 10.32388/7G3IND (preprint).</Citation></Reference><Reference><Citation>Ali A, Li X. Oncogenic Molecular Pathways: Mechanisms, Mutations and Inhibitors. Ann Hematol Oncol. 2016;3(8):1108.</Citation></Reference><Reference><Citation>Regad T. Targeting RTK signaling pathways in cancer. Cancers. 2015;7(3):1758–84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586793</ArticleId><ArticleId IdType="pubmed">26404379</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12(1):3–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5748484</ArticleId><ArticleId IdType="pubmed">29124875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman NE, Dhingra S, Jois SD, Vicente MD. Molecular targeting of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR). Molecules. 2021;26(4):1076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7922143</ArticleId><ArticleId IdType="pubmed">33670650</ArticleId></ArticleIdList></Reference><Reference><Citation>Stukalov A, Girault V, Grass V, Karayel O, Bergant V, Urban C, Haas DA, Huang Y, Oubraham L, Wang A, Hamad MS. Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV. Nature. 2021;594(7862):246–52.</Citation><ArticleIdList><ArticleId IdType="pubmed">33845483</ArticleId></ArticleIdList></Reference><Reference><Citation>Klann K, Bojkova D, Tascher G, Ciesek S, Münch C, Cinatl J. Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication. Mol Cell. 2020;80(1):164–74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7418786</ArticleId><ArticleId IdType="pubmed">32877642</ArticleId></ArticleIdList></Reference><Reference><Citation>Palakkott AR, Alneyadi A, Muhammad K, Eid AH, Amiri KM, Akli Ayoub M, Iratni R. The SARS-CoV-2 spike protein activates the epidermal growth factor receptor-mediated signaling. Vaccines. 2023;11(4):768.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10141239</ArticleId><ArticleId IdType="pubmed">37112680</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Z. Genomic instability and cancer: an introduction. J Mol Cell Biol. 2011;3(1):1–3.</Citation><ArticleIdList><ArticleId IdType="pubmed">21278445</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.</Citation><ArticleIdList><ArticleId IdType="pubmed">10647931</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SK, Kam H, Kim KY, Park SI, Lee YS. Targeting heat shock protein 27 in cancer: a druggable target for cancer treatment? Cancers. 2019;11(8):1195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6721579</ArticleId><ArticleId IdType="pubmed">31426426</ArticleId></ArticleIdList></Reference><Reference><Citation>Berti M, Cortez D, Lopes M. The plasticity of DNA replication forks in response to clinically relevant genotoxic stress. Nat Rev Mol Cell Biol. 2020;21(10):633–51.</Citation><ArticleIdList><ArticleId IdType="pubmed">32612242</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimoto FK. The proteins of severe acute respiratory syndrome coronavirus-2 (SARS CoV-2 or n-COV19), the cause of COVID-19. Protein J. 2020;39(3):198–216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7245191</ArticleId><ArticleId IdType="pubmed">32447571</ArticleId></ArticleIdList></Reference><Reference><Citation>Gioia U, Tavella S, Martínez-Orellana P, Cicio G, Colliva A, Ceccon M, Cabrini M, Henriques AC, Fumagalli V, Paldino A, Presot E. SARS-CoV-2 infection induces DNA damage, through CHK1 degradation and impaired 53BP1 recruitment, and cellular senescence. Nat Cell Biol. 2023;25(4):550–64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10104783</ArticleId><ArticleId IdType="pubmed">36894671</ArticleId></ArticleIdList></Reference><Reference><Citation>Victor J, Deutsch J, Whitaker A, Lamkin EN, March A, Zhou P, Botten JW, Chatterjee N. SARS-CoV-2 triggers DNA damage response in Vero E6 cells. Biochem Biophys Res Commun. 2021;19(579):141–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440005</ArticleId><ArticleId IdType="pubmed">34600299</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan X, Hao Q, Mu Y, Timani KA, Ye L, Zhu Y, Wu J. Nucleocapsid protein of SARS-CoV activates the expression of cyclooxygenase-2 by binding directly to regulatory elements for nuclear factor-kappa B and CCAAT/enhancer binding protein. Int J Biochem Cell Biol. 2006;38(8):1417–28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108415</ArticleId><ArticleId IdType="pubmed">16546436</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh B, Vincent L, Multani A, Lucci A. Cyclooxygenase-2 expression perturbs DNA damage checkpoint signaling in MCF10A breast epithelial cells. Cancer Res. 2007;67(9_Supplement):5234.</Citation></Reference><Reference><Citation>Singh B, Vincent L, Berry JA, Multani AS, Lucci A. Cyclooxygenase-2 expression induces genomic instability in MCF10A breast epithelial cells. J Surg Res. 2007;140(2):220–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17418864</ArticleId></ArticleIdList></Reference><Reference><Citation>Speed N, Blair IA. Cyclooxygenase-and lipoxygenase-mediated DNA damage. Cancer Metastasis Rev. 2011;30:437–47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3237763</ArticleId><ArticleId IdType="pubmed">22009064</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell Host Microbe. 2020;27(4):671–80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7142693</ArticleId><ArticleId IdType="pubmed">32183941</ArticleId></ArticleIdList></Reference><Reference><Citation>Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, Hirayama AV, Mastroiani F, Turtle CJ, Harhay MO, Legrand M. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8(12):1233–44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7567529</ArticleId><ArticleId IdType="pubmed">33075298</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharif-Askari NS, Sharif-Askari FS, Mdkhana B, Alsayed HA, Alsafar H, Alrais ZF, Hamid Q, Halwani R. Upregulation of oxidative stress gene markers during SARS-COV-2 viral infection. Free Radical Biol Med. 2021;20(172):688–98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233550</ArticleId><ArticleId IdType="pubmed">34186206</ArticleId></ArticleIdList></Reference><Reference><Citation>Karkhanei B, Ghane ET, Mehri F. Evaluation of oxidative stress level: total antioxidant capacity, total oxidant status and glutathione activity in patients with COVID-19. New Microbes New Infect. 2021;1(42):100897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8127525</ArticleId><ArticleId IdType="pubmed">34026228</ArticleId></ArticleIdList></Reference><Reference><Citation>Çakırca G, Damar Çakırca T, Üstünel M, Torun A, Koyuncu I. Thiol level and total oxidant/antioxidant status in patients with COVID-19 infection. Ir J Med Sci (1971-). 2021:1–6.</Citation></Reference><Reference><Citation>Lorente L, Martín MM, González-Rivero AF, Pérez-Cejas A, Cáceres JJ, Perez A, Ramos-Gómez L, Solé-Violán J, y Ramos JA, Ojeda N, Jiménez A. DNA and RNA oxidative damage and mortality of patients with COVID-19. Amer J Med Sci. 2021;361(5):585–90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7884223</ArticleId><ArticleId IdType="pubmed">33600784</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlie-Silva I, Araújo AP, Guimarães AT, Veras FP, Braz HL, de Pontes LG, Jorge RJ, Belo MA, Fernandes BH, Nóbrega RH, Galdino G. Toxicological insights of Spike fragments SARS-CoV-2 by exposure environment: A threat to aquatic health? J Hazard Mater. 2021;5(419):126463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8226002</ArticleId><ArticleId IdType="pubmed">34216962</ArticleId></ArticleIdList></Reference><Reference><Citation>Renaudin X. Reactive oxygen species and DNA damage response in cancer. Int Rev Cell Mol Biol. 2021;1(364):139–61.</Citation><ArticleIdList><ArticleId IdType="pubmed">34507782</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HN, Kawahara M, Vuong CK, Fukushige M, Yamashita T, Ohneda O. Sars-Cov-2 M protein facilitates malignant transformation of breast cancer cells. Front Oncol. 2022;7(12):923467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9209714</ArticleId><ArticleId IdType="pubmed">35747796</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma VK, Prateeksha, Singh SP, Singh BN, Rao CV, Barik SK. Nanocurcumin potently inhibits SARS-CoV-2 spike protein-induced cytokine storm by deactivation of MAPK/NF-κB signaling in epithelial cells. ACS Appl Bio Mater. 2022;5(2):483–91.</Citation><ArticleIdList><ArticleId IdType="pubmed">35112841</ArticleId></ArticleIdList></Reference><Reference><Citation>Faist A, Schloer S, Mecate-Zambrano A, Janowski J, Schreiber A, Boergeling Y, Conrad BC, Kumar S, Toebben L, Schughart K, Baumgardt M. Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier. Antiviral Res. 2023;1(209):105475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9677559</ArticleId><ArticleId IdType="pubmed">36423831</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S, Shafiei MS, Longoria C, Schoggins JW, Savani RC, Zaki H. SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway. Elife. 2021;6(10):e68563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8709575</ArticleId><ArticleId IdType="pubmed">34866574</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehlen P, Mehlen A, Guillet D, Preville X, Arrigo AP. Tumor necrosis factor-α induces changes in the phosphorylation, cellular localization, and oligomerization of human hsp27, a stress protein that confers cellular resistance to this cytokine. J Cell Biochem. 1995;58(2):248–59.</Citation><ArticleIdList><ArticleId IdType="pubmed">7673331</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh JI, Kim SU. Cytokines and growth factors induce HSP27 phosphorylation in human astrocytes. J Neuropathol Exp Neurol. 1995;54(4):504–12.</Citation><ArticleIdList><ArticleId IdType="pubmed">7541446</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha A, Anirvan P. Cancer progression in COVID-19: integrating the roles of renin angiotensin aldosterone system, angiopoietin-2, heat shock protein-27 and epithelial mesenchymal transition. Ecancermedicalscience. 2020;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7532023</ArticleId><ArticleId IdType="pubmed">33082849</ArticleId></ArticleIdList></Reference><Reference><Citation>Maximov GK, Maximov KG. The role of p53 tumor-suppressor protein in apoptosis and cancerogenesis. Biotechnol Biotechnol Equip. 2008;22(2):664–8.</Citation></Reference><Reference><Citation>Ozaki T, Nakagawara A. Role of p53 in cell death and human cancers. Cancers. 2011;3(1):994–1013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756401</ArticleId><ArticleId IdType="pubmed">24212651</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter M, Chen IP, Vallejo-Gracia A, Kim IJ, Bielska O, Lam VL, Hayashi JM, Cruz A, Shah S, Soveg FW, Gross JD. SIRT5 is a proviral factor that interacts with SARS-CoV-2 Nsp14 protein. PLoS Pathog. 2022;18(9):e1010811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9499238</ArticleId><ArticleId IdType="pubmed">36095012</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM, Huang DC. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005;19(11):1294–305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1142553</ArticleId><ArticleId IdType="pubmed">15901672</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Wang C, Tian Y, Yao Y, Mao J, Wang H, Li Z, Xu Y, Ye M, Wang L. SIRT5 promotes hepatocellular carcinoma progression by regulating mitochondrial apoptosis. J Cancer. 2019;10(16):3871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6636294</ArticleId><ArticleId IdType="pubmed">31333804</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan P, Ge W, Lei Z, Luo W, Liu Y, Guan Z, Chen L, Yu Z, Shen M, Hu D, Xiang Q. SARS-CoV-2 N protein enhances the anti-apoptotic activity of MCL-1 to promote viral replication. Signal Transduct Target Ther. 2023;8(1):194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169150</ArticleId><ArticleId IdType="pubmed">37160897</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Guo M, Wei H, Chen Y. Targeting MCL-1 in cancer: current status and perspectives. J Hematol Oncol. 2021;14(1):67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8061042</ArticleId><ArticleId IdType="pubmed">33883020</ArticleId></ArticleIdList></Reference><Reference><Citation>Flavahan WA, Gaskell E, Bernstein BE. Epigenetic plasticity and the hallmarks of cancer. Science. 2017;357(6348):eaal2380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5940341</ArticleId><ArticleId IdType="pubmed">28729483</ArticleId></ArticleIdList></Reference><Reference><Citation>Darwiche N. Epigenetic mechanisms and the hallmarks of cancer: An intimate affair. Am J Cancer Res. 2020;10(7):1954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7407342</ArticleId><ArticleId IdType="pubmed">32774995</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantor JR, Sabatini DM. Cancer cell metabolism: one hallmark, many faces. Cancer Discov. 2012;2(10):881–98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3491070</ArticleId><ArticleId IdType="pubmed">23009760</ArticleId></ArticleIdList></Reference><Reference><Citation>DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Science. Advances. 2016;2(5):e1600200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4928883</ArticleId><ArticleId IdType="pubmed">27386546</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammoudi N, Ahmed KB, Garcia-Prieto C, Huang P. Metabolic alterations in cancer cells and therapeutic implications. Chin J Cancer. 2011;30(8):508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4013402</ArticleId><ArticleId IdType="pubmed">21801600</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Xu J. DNA methyltransferases and their roles in tumorigenesis. Biomark Res. 2017;5:1–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5251331</ArticleId><ArticleId IdType="pubmed">28127428</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhammad JS, Saheb Sharif-Askari N, Cui ZG, Hamad M, Halwani R. SARS-CoV-2 infection-induced promoter hypomethylation as an epigenetic modulator of heat shock protein A1L (HSPA1L) gene. Front Genet. 2021;19(12):622271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7933663</ArticleId><ArticleId IdType="pubmed">33679887</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SI, Lee JH, Kim RK, Jung U, Kahm YJ, Cho EW, Kim IG. HSPA1L enhances cancer stem cell-like properties by activating IGF1Rβ and regulating β-catenin transcription. Int J Mol Sci. 2020;21(18):6957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7555772</ArticleId><ArticleId IdType="pubmed">32971893</ArticleId></ArticleIdList></Reference><Reference><Citation>Velastegui E, Vera E, Vanden Berghe W, Muñoz MS, Orellana-Manzano A. HLA-C: Evolution, epigenetics, and pathological implications in the major histocompatibility complex. Front Genet. 2023;3(14):1206034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10350511</ArticleId><ArticleId IdType="pubmed">37465164</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Han YS, Yoon YM, Yun CW, Yun SP, Kim SM, Kwon HY, Jeong D, Baek MJ, Lee HJ, Lee SJ. Role of HSPA1L as a cellular prion protein stabilizer in tumor progression via HIF-1α/GP78 axis. Oncogene. 2017;36(47):6555–67.</Citation><ArticleIdList><ArticleId IdType="pubmed">28759037</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Wang Z, Li X, Liu B, Liu M, Liu L, Chen S, Ren M, Wang Y, Yu M, Wang B. SHMT2 desuccinylation by SIRT5 drives cancer cell proliferation. Can Res. 2018;78(2):372–86.</Citation><ArticleIdList><ArticleId IdType="pubmed">29180469</ArticleId></ArticleIdList></Reference><Reference><Citation>Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866629</ArticleId><ArticleId IdType="pubmed">20303878</ArticleId></ArticleIdList></Reference><Reference><Citation>Amere Subbarao S. Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting. Inflammopharmacology. 2021;29(2):343–66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7959277</ArticleId><ArticleId IdType="pubmed">33723711</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsyth CB, Zhang L, Bhushan A, Swanson B, Zhang L, Mamede JI, Voigt RM, Shaikh M, Engen PA, Keshavarzian A. The SARS-CoV-2 S1 spike protein promotes MAPK and NF-kB activation in human lung cells and inflammatory cytokine production in human lung and intestinal epithelial cells. Microorganisms. 2022;10(10):1996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9607240</ArticleId><ArticleId IdType="pubmed">36296272</ArticleId></ArticleIdList></Reference><Reference><Citation>Kartikasari AE, Huertas CS, Mitchell A, Plebanski M. Tumor-induced inflammatory cytokines and the emerging diagnostic devices for cancer detection and prognosis. Front Oncol. 2021;11:692142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8294036</ArticleId><ArticleId IdType="pubmed">34307156</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL. ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020;19(3):1997–2007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7027163</ArticleId><ArticleId IdType="pubmed">32104259</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Ma C, Zhang Z, Zhang H, Hu H. NF-κB signaling in inflammation and cancer. Med Comm. 2021;2(4):618–53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8706767</ArticleId><ArticleId IdType="pubmed">34977871</ArticleId></ArticleIdList></Reference><Reference><Citation>Craddock V, Mahajan A, Spikes L, Krishnamachary B, Ram AK, Kumar A, Chen L, Chalise P, Dhillon NK. Persistent circulation of soluble and extracellular vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19. J Med Virol. 2023;95(2):e28568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10048846</ArticleId><ArticleId IdType="pubmed">36756925</ArticleId></ArticleIdList></Reference><Reference><Citation>Multhoff G, Molls M, Radons J. Chronic inflammation in cancer development. Front Immunol. 2012;2:98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3342348</ArticleId><ArticleId IdType="pubmed">22566887</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki YJ, Nikolaienko SI, Dibrova VA, Dibrova YV, Vasylyk VM, Novikov MY, Shults NV, Gychka SG. SARS-CoV-2 spike protein-mediated cell signaling in lung vascular cells. Vascul Pharmacol. 2021;137:106823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7680014</ArticleId><ArticleId IdType="pubmed">33232769</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HS, Signori E. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015;35:S185–98.</Citation><ArticleIdList><ArticleId IdType="pubmed">25818339</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcami A, Koszinowski UH. Viral mechanisms of immune evasion. Immunol Today. 2000;21(9):447–55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7141567</ArticleId><ArticleId IdType="pubmed">10953097</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini G, Aneja R. Cancer as a prospective sequela of long COVID-19. BioEssays. 2021;43(6):2000331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8206711</ArticleId><ArticleId IdType="pubmed">33914346</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Xie X, Tu Z, Fu J, Xu D, Zhou Y. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct Target Ther. 2021;6(1):255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8261820</ArticleId><ArticleId IdType="pubmed">34234112</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapti V, Tsaganos T, Vathiotis IA, Syrigos NK, Li P, Poulakou G. New insights into SARS-CoV-2 and cancer cross-talk: Does a novel oncogenesis driver emerge? Vaccines. 2022;10(10):1607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9611551</ArticleId><ArticleId IdType="pubmed">36298472</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafarzadeh A, Gosain R, Mortazavi SM, Nemati M, Jafarzadeh S, Ghaderi A. SARS-CoV-2 infection: a possible risk factor for incidence and recurrence of cancers. Int J Hematol Oncol Stem Cell Res. 2022;16(2):117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9547773</ArticleId><ArticleId IdType="pubmed">36304732</ArticleId></ArticleIdList></Reference><Reference><Citation>Huot N, Planchais C, Rosenbaum P, Contreras V, Jacquelin B, Petitdemange C, Lazzerini M, Beaumont E, Orta-Resendiz A, Rey FA, Reeves RK. SARS-CoV-2 viral persistence in lung alveolar macrophages is controlled by IFN-γ and NK cells. Nat Immunol. 2023;24(12):2068–79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10681903</ArticleId><ArticleId IdType="pubmed">37919524</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen Y, Li Y, Huang F, Luo B, Yuan Y, Xia B, Ma X, Yang T, Yu F, Liu J. The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-Ι. Proc Natl Acad Sci. 2021;118(23):e2024202118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8201919</ArticleId><ArticleId IdType="pubmed">34021074</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor BC, Balko JM. Mechanisms of MHC-I downregulation and role in immunotherapy response. Front Immunol. 2022;13:844866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8920040</ArticleId><ArticleId IdType="pubmed">35296095</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera T, Fernandez MA, Sierra A, Garrido A, Herruzo A, Escobedo A, Fabra A, Garrido F. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol. 1996;50(2):127–34.</Citation><ArticleIdList><ArticleId IdType="pubmed">8891736</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother. 2008;57:197–206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2082063</ArticleId><ArticleId IdType="pubmed">17622526</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819–29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5007206</ArticleId><ArticleId IdType="pubmed">27433843</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M, Karki R, Williams EP, Yang D, Fitzpatrick E, Vogel P, Jonsson CB, Kanneganti TD. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat Immunol. 2021;22(7):829–38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8882317</ArticleId><ArticleId IdType="pubmed">33963333</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafqat A, Shafqat S, Salameh SA, Kashir J, Alkattan K, Yaqinuddin A. Mechanistic insights into the immune pathophysiology of COVID-19; an in-depth review. Front Immunol. 2022;13:835104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989408</ArticleId><ArticleId IdType="pubmed">35401519</ArticleId></ArticleIdList></Reference><Reference><Citation>Toor D, Jain A, Kalhan S, Manocha H, Sharma VK, Jain P, Tripathi V, Prakash H. Tempering macrophage plasticity for controlling SARS-CoV-2 infection for managing COVID-19 disease. Front Pharmacol. 2020;11:570698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7596271</ArticleId><ArticleId IdType="pubmed">33178021</ArticleId></ArticleIdList></Reference><Reference><Citation>Paludan SR, Mogensen TH. Innate immunological pathways in COVID-19 pathogenesis. Sci Immunol. 2022;7(67):eabm5505.</Citation><ArticleIdList><ArticleId IdType="pubmed">34995097</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutilier AJ, Elsawa SF. Macrophage polarization states in the tumor microenvironment. Int J Mol Sci. 2021;22(13):6995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8268869</ArticleId><ArticleId IdType="pubmed">34209703</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Han J, Cheng X, Yu L, Zhang L, Wang W, Ni L, Wei C, Huang Y, Cheng Z. Reduced numbers of T cells and B cells correlates with persistent SARS-CoV-2 presence in non-severe COVID-19 patients. Sci Rep. 2020;10(1):17718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7573596</ArticleId><ArticleId IdType="pubmed">33077873</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015;6(6):e1792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4669840</ArticleId><ArticleId IdType="pubmed">26086965</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang HC, Wang SH, Fang GC, Chou WC, Liao CC, Sun CP, Jan JT, Ma HH, Ko HY, Ko YA, Chiang MT. Upregulation of PD-L1 by SARS-CoV-2 promotes immune evasion. J Med Virol. 2023;95(2):e28478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10107526</ArticleId><ArticleId IdType="pubmed">36609964</ArticleId></ArticleIdList></Reference><Reference><Citation>Saman H, Raza SS, Uddin S, Rasul K. Inducing angiogenesis, a key step in cancer vascularization, and treatment approaches. Cancers. 2020;12(5):1172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7281705</ArticleId><ArticleId IdType="pubmed">32384792</ArticleId></ArticleIdList></Reference><Reference><Citation>Majidpoor J, Mortezaee K. Angiogenesis as a hallmark of solid tumors-clinical perspectives. Cell Oncol. 2021;44:715–37.</Citation><ArticleIdList><ArticleId IdType="pubmed">33835425</ArticleId></ArticleIdList></Reference><Reference><Citation>Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020;5(1):28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7067809</ArticleId><ArticleId IdType="pubmed">32296047</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X, Ye F. Role of angiopoietins in development of cancer and neoplasia associated with viral infection. Cells. 2020;9(2):457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7072744</ArticleId><ArticleId IdType="pubmed">32085414</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortaz E, Jamaati H, Roofchayee ND, Sheikhzade H, Mirenayat M, Sadeghi M, Lookzadeh S, Dezfuli NK, Folkerts G, Mumby S, Garssen J. Decreased serum levels of angiotensin converting enzyme (ACE) 2 and enhanced cytokine levels with severity of COVID-19: normalisation upon disease recovery. Heliyon. 2022;8(2).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8847112</ArticleId><ArticleId IdType="pubmed">35187271</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, Gong Z, Zhang S, Zhou J, Cao K, Li X. Role of tumor microenvironment in tumorigenesis. J Cancer. 2017;8(5):761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5381164</ArticleId><ArticleId IdType="pubmed">28382138</ArticleId></ArticleIdList></Reference><Reference><Citation>Krock BL, Skuli N, Simon MC. Hypoxia-induced angiogenesis: good and evil. Genes Cancer. 2011;2(12):1117–33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3411127</ArticleId><ArticleId IdType="pubmed">22866203</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues-Ferreira S, Abdelkarim M, Dillenburg-Pilla P, Luissint AC, di-Tommaso A, Deshayes F, Pontes CL, Molina A, Cagnard N, Letourneur F, Morel M. Angiotensin II facilitates breast cancer cell migration and metastasis. PloS One. 2012;7(4):e35667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3334979</ArticleId><ArticleId IdType="pubmed">22536420</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Wang H, Li X, Cao M, Lu H, Meng Q, Pang H, Li H, Nadolny C, Dong X, Cai L. Ang II–AT1R increases cell migration through PI3K/AKT and NF-κB pathways in breast cancer. J Cell Physiol. 2014;229(11):1855–62.</Citation><ArticleIdList><ArticleId IdType="pubmed">24692224</ArticleId></ArticleIdList></Reference><Reference><Citation>Ino K, Shibata K, Kajiyama H, Yamamoto E, Nagasaka T, Nawa A, Nomura S, Kikkawa F. Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival. Br J Cancer. 2006;94(4):552–60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2361172</ArticleId><ArticleId IdType="pubmed">16434990</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrieta O, Villarreal-Garza C, Vizcaíno G, Pineda B, Hernández-Pedro N, Guevara-Salazar P, Wegman-Ostrosky T, Villanueva-Rodríguez G, Gamboa-Domínguez A. Association between AT1 and AT2 angiotensin II receptor expression with cell proliferation and angiogenesis in operable breast cancer. Tumor Biol. 2015;36:5627–34.</Citation><ArticleIdList><ArticleId IdType="pubmed">25682288</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinter M, Jain RK. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci Transl Med. 2017;9(410):eaan5616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5928511</ArticleId><ArticleId IdType="pubmed">28978752</ArticleId></ArticleIdList></Reference><Reference><Citation>Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet AL, Latreche S, Bergaya S, Benhamouda N, Tanchot C, Stockmann C. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212(2):139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4322048</ArticleId><ArticleId IdType="pubmed">25601652</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY, Maceyka M, Jiang H, Luo C, Kordula T, Milstien S. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature. 2010;465(7301):1084–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2946785</ArticleId><ArticleId IdType="pubmed">20577214</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan SA, Goliwas KF, Deshane JS. Sphingolipids in lung pathology in the coronavirus disease era: A review of sphingolipid involvement in the pathogenesis of lung damage. Front Physiol. 2021;12:760638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8531546</ArticleId><ArticleId IdType="pubmed">34690821</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragunathrao VA, Anwar M, Akhter MZ, Chavez A, Natarajan V, Lakshmikanthan S, Chrzanowska-Wodnicka M, Dudek AZ, Claesson-Welsh L, Kitajewski JK, Wary KK. Sphingosine-1-phosphate receptor 1 activity promotes tumor growth by amplifying VEGF-VEGFR2 angiogenic signaling. Cell Rep. 2019;29(11):3472–87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6927555</ArticleId><ArticleId IdType="pubmed">31825830</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan EM, Haddadi N, Nassif NT, Lin Y. Targeting the SphK-S1P-SIPR pathway as a potential therapeutic approach for COVID-19. Int J Mol Sci. 2020;21(19):7189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7583882</ArticleId><ArticleId IdType="pubmed">33003377</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitson SM. Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem Sci. 2011;36(2):97–107.</Citation><ArticleIdList><ArticleId IdType="pubmed">20870412</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuvillier O, Ader I, Bouquerel P, Brizuela L, Gstalder C, Malavaud B. Hypoxia, therapeutic resistance, and sphingosine 1-phosphate. Adv Cancer Res. 2013;117:117–41.</Citation><ArticleIdList><ArticleId IdType="pubmed">23290779</ArticleId></ArticleIdList></Reference><Reference><Citation>Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 2012;22(1):50–60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3253987</ArticleId><ArticleId IdType="pubmed">22001186</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogretmen B. Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer. 2018;18(1):33–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5818153</ArticleId><ArticleId IdType="pubmed">29147025</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano T, Murakami M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity. 2020;52(5):731–3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7175868</ArticleId><ArticleId IdType="pubmed">32325025</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai YJ, Chao CH, Liao CC, Lee TA, Hsu JM, Chou WC, Wang J, Huang HC, Chang SJ, Lin YL, Li CW. Epithelial-mesenchymal transition induced by SARS-CoV-2 required transcriptional upregulation of Snail. Am J Cancer Res. 2021;11(5):2278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8167694</ArticleId><ArticleId IdType="pubmed">34094684</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang HC, Liao CC, Wang SH, Lee IJ, Lee TA, Hsu JM, Kuo CT, Wang J, Hsieh WC, Chang SJ, Chen SY. Hyperglycosylated spike of SARS-CoV-2 gamma variant induces breast cancer metastasis. Am J Cancer Res. 2021;11(10):4994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8569360</ArticleId><ArticleId IdType="pubmed">34765306</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Kundu ST, Diao L, Wang Q. SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2 in lung cancer models. bioRxiv 2020.05.28.122291. 10.1101/2020.05.28.122291.</Citation></Reference><Reference><Citation>Ciszewski WM, Wozniak LA, Sobierajska K. SARS-CoV-2 S and N protein peptides drive invasion abilities of colon cancer cells through TGF-β1 regulation. Biochim Biophys Acta Mol Cell Res. 2023;1870(7):119541.</Citation><ArticleIdList><ArticleId IdType="pubmed">37468071</ArticleId></ArticleIdList></Reference><Reference><Citation>He R, Leeson A, Andonov A, Li Y, Bastien N, Cao J, Osiowy C, Dobie F, Cutts T, Ballantine M, Li X. Activation of AP-1 signal transduction pathway by SARS coronavirus nucleocapsid protein. Biochem Biophys Res Commun. 2003;311(4):870–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7111052</ArticleId><ArticleId IdType="pubmed">14623261</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazon H, Barbeau B, Mesnard JM, Peloponese JM Jr. Hijacking of the AP-1 signaling pathway during development of ATL. Front Microbiol. 2018;8:2686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5775265</ArticleId><ArticleId IdType="pubmed">29379481</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding X, Pan H, Li J, Zhong Q, Chen X, Dry SM, Wang CY. Epigenetic activation of AP1 promotes squamous cell carcinoma metastasis. Sci Signal. 2013;6(273):ra28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3951265</ArticleId><ArticleId IdType="pubmed">23633675</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizutani T, Fukushi S, Saijo M, Kurane I, Morikawa S. Phosphorylation of p38 MAPK and its downstream targets in SARS coronavirus-infected cells. Biochem Biophys Res Commun. 2004;319(4):1228–34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7111015</ArticleId><ArticleId IdType="pubmed">15194498</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Tsai MC, Tu W, Yeh HC, Wang SC, Huang SP, Li CY. Role of the NLRP3 inflammasome: insights into cancer hallmarks. Front Immunol. 2021;11:610492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7886802</ArticleId><ArticleId IdType="pubmed">33613533</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratajczak MZ, Kucia M. SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine “storm” and risk factor for damage of hematopoietic stem cells. Leukemia. 2020;34(7):1726–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262681</ArticleId><ArticleId IdType="pubmed">32483300</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan P, Shen M, Yu Z, Ge W, Chen K, Tian M, Xiao F, Wang Z, Wang J, Jia Y, Wang W. SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation. Nat Commun. 202AD;12(1):4664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8329225</ArticleId><ArticleId IdType="pubmed">34341353</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin S, Aktar S, Rahman MM, Chowdhury MM. NLRP3 inflammasome activation in COVID-19: an interlink between risk factors and disease severity. Microbes Infect. 2022;24(1):104913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8613976</ArticleId><ArticleId IdType="pubmed">34838941</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamarsheh SA, Zeiser R. NLRP3 inflammasome activation in cancer: a double-edged sword. Front Immunol. 2020;11:1444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7360837</ArticleId><ArticleId IdType="pubmed">32733479</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Kong H, Zeng X, Liu W, Wang Z, Yan X, Wang H, Xie W. Activation of NLRP3 inflammasome enhances the proliferation and migration of A549 lung cancer cells. Oncol Rep. 2016;35(4):2053–64.</Citation><ArticleIdList><ArticleId IdType="pubmed">26782741</ArticleId></ArticleIdList></Reference><Reference><Citation>Shadab A, Mahjoor M, Abbasi-Kolli M, Afkhami H, Moeinian P, Safdarian AR. Divergent functions of NLRP3 inflammasomes in cancer: a review. Cell Commun Signal. 2023;21(1):232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10503066</ArticleId><ArticleId IdType="pubmed">37715239</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge H, Li L, Zhang D, Ma F. Applications of digital medicine in oncology: prospects and challenges. Cancer Innov. 2022;1(4):285–92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10686176</ArticleId><ArticleId IdType="pubmed">38089082</ArticleId></ArticleIdList></Reference><Reference><Citation>Klock C, Soares FA. Cancer diagnosis in the post-coronavirus disease era: the promising role of telepathology and artificial intelligence. Rev Assoc Med Bras. 2024;70(suppl 1):e2024S127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11164283</ArticleId><ArticleId IdType="pubmed">38865546</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisapia P, Pepe F, Gristina V, La Mantia M, Francomano V, Russo G, Iaccarino A, Galvano A. A narrative review on the implementation of liquid biopsy as a diagnostic tool in thoracic tumors during the COVID-19 pandemic. Mediastinum. 2021;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8794438</ArticleId><ArticleId IdType="pubmed">35118332</ArticleId></ArticleIdList></Reference><Reference><Citation>Masoomikarimi M, Garmabi B, Alizadeh J, Kazemi E, Jafari AA, Mirmoeeni S, Dargahi M, Taheri N, Jafari R. Advances in immunotherapy for COVID-19: A comprehensive review. Int Immunopharmacol. 2021;93:107409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7826020</ArticleId><ArticleId IdType="pubmed">33581501</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorat N, Pricl S, Parchur AK, Somvanshi SB, Li Q, Umrao S, Townley H. Safeguarding COVID-19 and cancer management: drug design and therapeutic approach. Open Res Eur. 2021;1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10445946</ArticleId><ArticleId IdType="pubmed">37645153</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>